Vertaling van "national consultation platforms with other " (Nederlands → Frans) :

In order to carry out its various tasks optimally, the FAMHP enlists the help of the FAMHP commissions, the national consultation platforms with other government services, institutions and stakeholders and the FAMHP representatives on national and international commissions, committees and working groups.
In order to carry out its various tasks optimally, the FAMHP enlists the help of the FAMHP commissions, the national consultation platforms with other government services, institutions and stakeholders and the FAMHP representatives on national and international commissions, committees and working groups.

and Public Health Minister’s office “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS
and Public Health Minister’s office “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS

Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)
Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)

BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council
BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council

BAPCOC (with FPS Public Health) Board for biosafety (with WIV - ISP and the Biosafety and Biotechnology Service) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Professional Ethics Committee (with FPS Public Health - DG Animals - Plants - Foodstuffs) Strategic unit/RIZIV - INAMI
BAPCOC (with FPS Public Health) Board for biosafety (with WIV - ISP and the Biosafety and Biotechnology Service) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Professional Ethics Committee (with FPS Public Health - DG Animals - Plants - Foodstuffs) Strategic unit/RIZIV - INAMI

Regular consultation platforms with other government services and institutions such as: ●● BAPCOC (with FPS Public Health) ●● Board for biosafety (with WIV - ISP and the
Regular consultation platforms with other government services and institutions such as: ●● BAPCOC (with FPS Public Health) ●● Board for biosafety (with WIV - ISP and the

National –– 10 meetings of the evaluation commissions –– 4 gatherings of the consultation platform –– 12 gatherings of the “grey area” consultation platform –– 12 meetings of the technical implants
National –– 10 meetings of the evaluation commissions –– 4 gatherings of the consultation platform –– 12 gatherings of the “grey area” consultation platform –– 12 meetings of the technical implants

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

2000 € Minimal counselling by a GP consists of one or two consultations with a total length of 12 minutes, not provided as part of a consultation for other health reasons Minimal counselling+NRT is provided for a period of 8 weeks Intensive counselling+NRT is provided by a trained lung nurse for a total of 90 minutes after a brief advice from a lung physician, period of NRT is 12 weeks Intensive counselling+bupropion included intensive counselling as described above with bupropion for a period of 9 weeks Telephone counselling consists of one intake call of 30 minutes and six follow-up calls of each 15 minutes Costs of self-help materials was included One defined daily dose (DDD) equals 14 mg for NRT patches.
2000 € Minimal counselling by a GP consists of one or two consultations with a total length of 12 minutes, not provided as part of a consultation for other health reasons Minimal counselling+NRT is provided for a period of 8 weeks Intensive counselling+NRT is provided by a trained lung nurse for a total of 90 minutes after a brief advice from a lung physician, period of NRT is 12 weeks Intensive counselling+Buproprion included intensive counselling as described above with Buproprion for a period of 9 weeks Telephone counselling consists of one intake call of 30 minutes and six follow-up calls of each 15 minutes Costs of self-help materials was included One defined daily dose (DDD) equals 14 mg for NRT patches.

Over the last few years, the term “depressiveness”, which is treated as a synonym of depression by some and as a term indicating a specific and independent state by others, has appeared in various national and international articles in order to provide a better definition for an intermediate state that does not fit into the category of depression in the strict sense but which is nevertheless characterised by psychic suffering and a difficulty with life.
Synonyme de la dépression pour certains, état spécifique et indépendant pour d’autres, le terme de « dépressivité » est apparu ces dernières années dans différents articles tant au niveau national qu’international en vue de mieux cerner un état intermédiaire qui ne pouvait relever du domaine de la dépression au sens strict mais qui montrait tout de même une certaine souffrance psychique, une difficulté à vivre.